Ultrasound-guided percutaneous microwave ablation as first-line treatment for HCC: A study on clinical efficacy and prognostic factors

Abstract

Abstract: Objective To investigate the clinical efficacy of ultrasound (US)-guided percutaneous microwave ablation as a first-line treatment for hepatocellular carcinoma (HCC), and its prognostic factors analysis.Methods From June 2010 to November 2014, 201 patients who were first diagnosed HCC and receiving US-guided microwave ablation treatment in Shanghai Renji hospital were enrolled, and followed up for 4 to 53 months. Univariate (Kaplan-Meier method) and multivariate (Cox-regression) analysis were applied to determine the prognostic factors for progression-free survival and overall survival.Results Complete ablation rate after first ablation was 96%. For some patients receiving a second ablation, the total complete ablation rate was 99%. Twelve of the 201 (5.6%) patients suffered ablation associated complications. Mean progression-free survival (PFS) of microwave ablation therapy was 18 months. In addition, liver function Child B, multiple tumors, tumor diameter > 5 cm and AFP>20 were independent risk factors associated with worse PFS. Hepatitis history, multiple tumors and tumor diameter > 5cm were independent predictors for overall survival (OS) of which mean value was 38 months.Conclusion US-guided microwave ablation as a first-line therapy for HCC is safe and efficacious. Tumor diameter, tumor number and liver status of patients might be main prognostic factors affecting PFS and OS.

Key words: HCC; Microwave ablation; Clinical efficacy; Prognosis

MA Si-cong, WANG Tao, DING Min, MING Ya-nan, QI Xing-xing, ZHANG Yuan, ZHAI Bo. Ultrasound-guided percutaneous microwave ablation as first-line treatment for HCC: A study on clinical efficacy and prognostic factors[J]. Chinese Hepatolgy, 2016, 21(5): 355-359.

References

[1] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55: 74-108.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65: 87-108.
[3] Lee WC, Jeng LB, Chen MF. Estimation of prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg, 2002, 89: 311-316.
[4] Fan ST, Poon RT, Yeung C, et al. Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria. Br J Surg, 2011, 98: 1292-300.
[5] Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol, 2007, 17: 684-692.
[6] Kim YS, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol, 2013, 58: 89-97.
[7] Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol, 2012, 57: 794-802.
[8] Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg, 2006, 243: 321-328.
[9] Shi J, Sun Q, Wang Y, et al. Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria. J Gastroenterol Hepatol, 2014, 29: 1500-1507.
[10] Ni JY, Xu LF, Sun HL, et al. Percutaneous ablation therapy versus surgical resection in the treatment for early-stage hepatocellular carcinoma: a meta-analysis of 21,494 patients. J Cancer Res Clin Oncol, 2013, 139: 2021-2033.
[11] Yin XY, Xie XY, Lu MD, et al. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer, 2009, 115: 1914-1923.
[12] Lu MD, Yin XY, Xie XY, et al. Percutaneous thermal ablation for recurrent hepatocellular carcinoma after hepatectomy. Br J Surg, 2005, 92: 1393-1398.
[13] Martin RC, Scoggins CR, Mcmasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol, 2010, 17: 171-178.
[14] Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol, 2012, 107: 569-77; quiz 78.
[15] Veltri A, Moretto P, Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol, 2006, 16: 661-669.
[16] 陈俊卯, 刘艳华, 陈建立, 等. 无水酒精注射联合射频消融治疗射频消融困难部位的肝癌. 现代肿瘤医学, 2012, 20: 122-124.